Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal; Toxfinder, Lda, 3030-199 Coimbra, Portugal; Center for Neuroscience and Cell Biology - CNC, University of Coimbra, 3004-504 Coimbra, Portugal.
Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal; Coimbra Chemistry Center, Department of Chemistry, University of Coimbra, 3004-535 Coimbra, Portugal.
Int J Pharm. 2022 Nov 25;628:122265. doi: 10.1016/j.ijpharm.2022.122265. Epub 2022 Oct 8.
Allergic contact dermatitis (ACD) is the most prevalent occupational disease and the most common form of immunotoxicity in humans. Preventing exposure to the triggering allergens is the mainstay of treatment. However, avoidance is not always possible in an occupational setting. From a pathophysiological point of view, a variety of events are involved in the development of ACD, including the formation of immunogenic complexes following the stable association of the allergen with skin proteins, which is thought to be the molecular initiating event responsible for the development of ACD. Previously, the team identified molecules that exhibited higher antiallergic potential due to their capacity to block the interaction between allergens and skin proteins. These assumptions were the starting point for the design of this work aiming to develop and characterize a new hydrogel containing the active ingredients lysine and N-acetyl cysteine under the premises of quality- and safety- by design. Two factorial plannings were established envisioning the optimization of the hydrogel in terms of mechanical and rheological properties. In vitro release and permeation studies supported its skin surface barrier effect. In addition, the selected hydrogel proved to be safe without causing human skin irritation or skin sensitization.
变应性接触性皮炎（ACD）是最常见的职业病，也是人类最常见的免疫毒性形式。预防接触引发过敏的过敏原是治疗的主要方法。然而，在职业环境中，避免接触并不总是可行的。从病理生理学的角度来看，ACD 的发展涉及多种事件，包括过敏原与皮肤蛋白稳定结合后形成免疫原性复合物，这被认为是导致 ACD 发展的分子起始事件。此前，该团队发现了一些由于能够阻断过敏原与皮肤蛋白之间相互作用而表现出更高抗过敏潜力的分子。这些假设是设计这项工作的起点，目的是在质量源于设计和安全源于设计的前提下，开发和表征一种含有赖氨酸和 N-乙酰半胱氨酸的新型水凝胶。建立了两个析因规划，设想根据机械和流变性能优化水凝胶。体外释放和渗透研究支持其皮肤表面屏障作用。此外，所选水凝胶被证明是安全的，不会引起人体皮肤刺激或皮肤致敏。
